Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares fell 23.3% to $2.47 after the company reported results from the second FIT Phase 3 study for fostamatinib. The company disclosed that the study did not meet primary endpoint. Share volume was 13.7 million, towering over an all-day average of 2.1 million
